(CercleFinance.com) – Néovacs announced on Wednesday the superiority of its therapeutic messenger RNA (mRNA) vaccine compared to the protein vaccine in a preclinical trial for the treatment of allergies.
The biopharmaceutical company indicates that the administration of its new mRNA technology was carried out without adverse effects in non-human primates.
The study also showed the induction of a neutralizing response against the circulating cytokines IL-4 and IL-13 IL-4 and IL-13.
Three-month data also demonstrated significantly greater effectiveness of mRNA vaccines compared to protein vaccines.
In view of these results, Néovacs decided to extend the duration of this study to measure the effectiveness of mRNA type vaccines in the long term, that is to say over a period of six months.
From the company’s point of view, this study validates the tolerance and effectiveness of its approach, which encourages it to continue clinical development with its mRNA vaccines in allergy.
The company indicates that it is now preparing the necessary steps to launch a Phase I/IIa trial in humans.
After opening up 18%, the stock turned downward mid-morning and was down more than 10% at the end of the morning.